Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount


REUTERS: Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of US$4,175 per unit set by Coherus is the same as Mylan NV's biosimilar Fulphila that was approved earlier this year.



from Biotech News